Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients
Launched by UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN · Sep 21, 2010
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
Assisted reproduction by in-vitro fertilisation plays a pivotal role in the treatment of infertility, the understanding of reproductive biology, and future population dynamics. The success of assisted reproductive technologies (ART) is critically dependent on optimizing protocols for controlled ovarian stimulation which aim at providing an adequate number of good quality oocytes for in-vitro laboratory procedures. Interindividual variation in response to follicle-stimulating hormone (FSH) is a widespread problem with clinical and economical implications. A group of patients (9%-24%) tend to...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female patients for who the treating physician decides that treatment with long acting FSH 150µg in a GnRH-antagonist protocol is indicated.
- Exclusion Criteria:
- • Contraindications for the use of gonadotropins (e.g., tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts) Use of hormonal preparations within one month prior to inclusion
About University Hospital Schleswig Holstein
University Hospital Schleswig-Holstein (UKSH) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution, UKSH integrates cutting-edge medical research with comprehensive patient care, fostering an environment that promotes the development of novel therapeutic strategies. With a multidisciplinary approach and a strong emphasis on collaboration, UKSH is dedicated to enhancing clinical outcomes and contributing to the global medical community through rigorous scientific inquiry and the translation of research findings into practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Haugesund, , Norway
Kiel, S H, Germany
Luebeck, Schleswig Holstein, Germany
Münster, , Germany
Würzburg, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials